White Paper

KRAS Biomarker Becomes a Target of Choice in Certain Cancer Therapies

Download  White Paper

Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target

In this white paper, find out more about:

  • The structure and function of the RAS protein superfamily
  • The role and consequences of KRAS gene activation
  • How renowned companies are targeting KRAS in cancer therapies and what the current challenges in developing KRAS-targeted therapeutics are
  • How to identify novel KRAS inhibitors and how to characterize downstream KRAS signaling with Alpha Surefire® Ultra and HTRF® technologies

Download  White Paper

We are committed to your privacy. Revvity needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our  Privacy Policy.